Amylyx Pharmaceuticals (AMLX) Stock Still Trades At A Premium As Phase 3 Progress Advances

Simply Wall St.11-09

Amylyx Pharmaceuticals has surged on strong trial news and investor interest, and the question now is whether a move like this can be squared with what the balance sheet says the business is worth on ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682382329?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","is_english":true,"pubTime":"2026-11-09 00:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682382329","market":"hk","top_or_hot":-1,"title":"Amylyx Pharmaceuticals (AMLX) Stock Still Trades At A Premium As Phase 3 Progress Advances","media":"Simply Wall St.","content":"<div>\n<p>Amylyx Pharmaceuticals has surged on strong trial news and investor interest, and the question now is whether a move like this can be squared with what the balance sheet says the business is worth on ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-stock-still-trades-at-a-premium\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amylyx Pharmaceuticals (AMLX) Stock Still Trades At A Premium As Phase 3 Progress Advances</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmylyx Pharmaceuticals (AMLX) Stock Still Trades At A Premium As Phase 3 Progress Advances\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-09 00:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-stock-still-trades-at-a-premium><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amylyx Pharmaceuticals has surged on strong trial news and investor interest, and the question now is whether a move like this can be squared with what the balance sheet says the business is worth on ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-stock-still-trades-at-a-premium\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4097","symbol_name":"系统软件","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-stock-still-trades-at-a-premium","article_id":"2682382329","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/amylyx-pharmaceuticals-amlx-stock-still-trades-at-a-premium","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682382329","pubTimestamp":1794154716,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 8, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4097":"系统软件","AMLX":"Amylyx Pharmaceuticals","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4007":"制药","PRGS":"Progress Software Corporation","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"随着第三阶段进展的推进，Amylyx Pharmaceuticals (AMLX) 股票交易仍溢价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"AMLX":0.9},"content_text":"Amylyx Pharmaceuticals has surged on strong trial news and investor interest, and the question now is whether a move like this can be squared with what the balance sheet says the business is worth on paper. With Amylyx stock already pricing in a lot of optimism, the focus turns to how that share price lines up against its book value and the broader industry average.  Amylyx is up 158.3% year to date, which puts real pressure on investors to ask how much of that jump is backed by its underlying net assets. Positive Phase 3 LUCIDITY results for avexitide and a cash position reported at US$768.1m after a US$545m equity raise can affect how investors weigh future capital needs against current book equity. Your read on Amylyx Pharmaceuticals is one view; the desks covering it have another. See what analysts think Amylyx Pharmaceuticals's shares could be worth.  The issue now is whether Amylyx Pharmaceuticals' recent share price is adequately supported by its book value when compared with the industry average. If you want to test this same book value question across a wider set of opportunities, you can scan through 38 high quality undervalued stocks. AdvertisementHas Amylyx Pharmaceuticals Run Too Far on Book Value? P/B suits Amylyx Pharmaceuticals because the balance sheet and cash position are front and center after the recent equity raise. The stock trades on a P/B of 5.0x, which is well above the Pharmaceuticals industry average of 1.9x and also above the peer group on 3.8x. That gap signals investors are paying a clear premium to the sector for each dollar of net assets on Amylyx's books. Because the Phase 3 LUCIDITY data and strong cash balance have lifted expectations, that premium looks ambitious rather than conservative when judged against the wider industry. The P/B multiple therefore points to Amylyx stock pricing in a rich valuation relative to typical Pharmaceuticals peers, and any holder needs to weigh how much confidence they have that the current pipeline justifies that higher bar. Explore the numbers behind Amylyx Pharmaceuticals's P/B valuation. NasdaqGS:AMLX P/B Ratio as at Nov 2026 The Amylyx Pharmaceuticals Narrative: What Would Justify Today's Price? Narratives for Amylyx Pharmaceuticals pick up where the price to book puzzle leaves off and explain which paths for growth, profitability and earnings would need to occur for the shares to be worth materially more or less than they are today on the market. Rather than relying on a single ratio or model output, they describe the future performance underlying that figure so you can watch whether the real Amylyx Pharmaceuticals story continues to align with those expectations. Bullish holders see Amylyx Pharmaceuticals as building a rare disease franchise, while skeptics think expectations for avexitide and PBH are already stretched. Bull case: 48% undervalued \"Bullish analysts expect Amylyx Pharmaceuticals to turn avexitide and its broader rare disease pipeline into a durable PBH and endocrine franchise...\" Discover why this Narrative puts Amylyx Pharmaceuticals at 48% undervalued. Bear case: 24% overvalued \"Bearish analysts caution that current targets already bake in optimistic assumptions on avexitide pricing and uptake, which could leave limited room for upside...\" Explore why this Narrative puts Amylyx Pharmaceuticals at 24% overvalued. Amylyx Pharmaceuticals: One More Piece Before You Decide Price, book value and pipeline expectations only tell part of the Amylyx Pharmaceuticals story. Recent trading by people inside the business can offer a very different clue about conviction, and the specific sellers, sizes and context are all laid out for you to review. See the recent insider selling flagged for Amylyx Pharmaceuticals. NasdaqGS:AMLX Insider Trading Volume as at Nov 2026 This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682382329","isCrawlerRequest":true}